Immunotherapy, which has been found to improve OS in patients with prostate cancer, is an ideal treatment modality as prostate cancer cells express unique proteins, such as PSA and PSMA, that can act as therapeutic targets for the immune system [29]. Here, FOLH1 is linked to prostate carcinoma.